Abstract Number: 032 • 2026 Pediatric Rheumatology Symposium
Methotrexate Response in Systemic JIA: Real-World Evidence from a Tertiary-Care Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) shows heterogeneous disease trajectories, and the subset of patients who achieve remission with methotrexate (MTX) monotherapy is not well…Abstract Number: 003 • 2026 Pediatric Rheumatology Symposium
Dysregulated Macrophage–Fibroblast Crosstalk Identified by Single-Cell RNA-seq in Juvenile Systemic Scleroderma Skin
Background/Purpose: Juvenile systemic scleroderma (jSSc) is a rare autoimmune disease characterized by progressive fibrosis and vascular dysfunction. Although jSSc shares important clinical features with adult…Abstract Number: 026 • 2026 Pediatric Rheumatology Symposium
Treatment strategies for articular flares in JIA patients receiving biologic therapy
Background/Purpose: Biologic agents form the cornerstone of therapy for Juvenile Idiopathic Arthritis (JIA); however, the optimal management of flares that occur during ongoing treatment remains…Abstract Number: 055 • 2026 Pediatric Rheumatology Symposium
Referrals Leading to Rheumatologic Diagnosis in a Pediatric Rheumatology Center: Influence of Referring Provider Practice and Training
Background/Purpose: Recently, there has been a dramatic increase in referrals made to pediatric rheumatologists (PR) for non-specific symptoms and test results rather than overt signs…Abstract Number: 015 • 2026 Pediatric Rheumatology Symposium
Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial
Background/Purpose: The REGENCY trial (NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at…Abstract Number: 016 • 2026 Pediatric Rheumatology Symposium
Still’s Disease Associated Lung Disease: Experience from a Tertiary Italian Centre
Background/Purpose: Still’s Disease (SD)-associated lung disease (SD-LD) is a severe potentially life-threatening condition characterized by peculiar features. For the rarity of this condition, the experience…Abstract Number: 005 • 2026 Pediatric Rheumatology Symposium
Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study
Background/Purpose: Musculoskeletal (MSK) manifestations are amongst the most common extraintestinal manifestations (EIMs) in pediatric Crohn’s disease (CD). MSK EIMs contribute to reduced quality of life…Abstract Number: 067 • 2026 Pediatric Rheumatology Symposium
Standardizing Effective Education and Intervention for Chronic Non-Inflammatory Pain in Children with Juvenile Idiopathic Arthritis: A Quality Improvement Initiative
Background/Purpose: 5-10% of patients with juvenile idiopathic arthritis (JIA) can have chronic pain lasting >3 months despite well-controlled disease. This pain is from altered pain-related sensory pathways in the periphery and central…Abstract Number: 035 • 2026 Pediatric Rheumatology Symposium
Healthcare and Medication Utilization Before and After JIA diagnosis in Publicly Insured Children in the United States
Background/Purpose: We assessed patterns of healthcare and medication utilization in children newly diagnosed with JIA compared to matched children without JIA. We hypothesized that healthcare…Abstract Number: 044 • 2026 Pediatric Rheumatology Symposium
Efficacy of Rituximab Biosimilars in Pediatric ANCA-Associated Vasculitis
Background/Purpose: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a severe small vessel vasculitis. Rituximab is a monoclonal anti-CD20 antibody that is effective for induction and maintenance…Abstract Number: 024 • 2026 Pediatric Rheumatology Symposium
Therapeutic Plasma Exchange in Pediatric Autoimmune Encephalitis
Background/Purpose: Autoimmune encephalitis (AE) is a severe neuroinflammatory disorder mediated by antibodies against neuronal receptors. Therapeutic plasma exchange (TPE) can remove autoantibodies, immune complexes, and…Abstract Number: 037 • 2026 Pediatric Rheumatology Symposium
Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
Background/Purpose: Childhood-onset systemic lupus erythematosus (SLE) is typically more severe than adult-onset disease, with higher morbidity, organ damage, and mortality. Despite this, pediatric drug trials…Abstract Number: 040 • 2026 Pediatric Rheumatology Symposium
Antiphospholipid Antibody-Mediated Disease: Clinical Characteristics and Outcomes of Catastrophic Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia in a Single Center Pediatric Cohort
Background/Purpose: Catastrophic antiphospholipid syndrome (CAPS) and lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) represent distinct yet closely related antiphospholipid antibody-driven disease entities, caused by immune-mediated dysregulation of…Abstract Number: 052 • 2026 Pediatric Rheumatology Symposium
Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy
Background/Purpose: Systemic juvenile idiopathic arthritis-associated lung disease (sJIA-LD) is a rare, potentially fatal complication of sJIA, often accompanied by pulmonary hypertension (PH) and macrophage activation…Abstract Number: 018 • 2026 Pediatric Rheumatology Symposium
Abnormal Cortical Grey Matter, White Matter and Subcortical Grey Matter Morphometry is Associated with Disease Features and Quality of Life in Patients with Craniofacial Localized Scleroderma
Background/Purpose: Craniofacial localized scleroderma (Cf-LS) is a rare autoimmune disorder that affects face and scalp tissues and is often diagnosed during childhood. Children with Cf-LS…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 2616
- Next Page »